Meet the current Society board

Executive Positions

Ann Hoffman
Ann HoffmanPresident
Ann was elected as president of the society in 2020. She has been a pivotal member of the council and society for several years and is currently an investigator at GSK involved in High Content Imaging and Drug Design and Selection.

Investigator
GlaxoSmithKline
Collegeville, PA

 

 

Debra Nickischer
Debra NickischerSecretary
Debby was elected Secretary Elect of SBI2 in 2019 and moved to Secretary in 2020. Debby has been heavily involved in the board and society for many years. She is currently a Research Scientist at Arvinas using her 20 years of high content imaging experience to help with Lead Discovery efforts.

Research Scientist
Arvinas
New Haven, CT

 

Jeff Haskins
Jeff HaskinsTreasurer
Jeff is currently an Executive Director of Global In Vitro Toxicology at Charles River Laboratories. He has over 30 years experience in cellular imaging and toxicology. Jeff was previously a senior research associate at Pfizer in the Discovery Toxicology Group and R&D Director at Thermo Fisher Scientific.

Executive Director, Global In Vitro Toxicology
Charles River Laboratories, Cleveland, OH

Judi Wardwell
Judi WardwellPresident-Elect
Judi Wardwell-Swanson is a Sr. Application Scientist at InSphero, Inc. where she assists Pharma, Biotech and Academic scientists integrate multicellular 3D models derived from human donor tissues into their drug discovery workflow. In addition to her role as InSphero’s Senior Application Scientist, she also serves as the lead scientist for their high content imaging strategy and technical advisor for their newly acquired imaging platform. Judi has been an active member of SBI2 for 5 years, serving as a Councilor on the Board of Directors from 2016-2019 and currently serving as President Elect.
Myles Fennel
Myles FennelPast President
Myles is the current past president of the society (2018 to 2019)

2020 Scientific Program Chairs

Beth Cimini
Beth Cimini
Broad Institute of MIT & Harvard
Paul Johnston
Paul Johnston
University of Pittsburgh
Joe Trask
Joe Trask
PerkinElmer

Council

Shannon Mumenthaler
University of Southern California

Shannon Mumenthaler, PhD, is an Assistant Professor of Medicine and Biomedical Engineering at the University of Southern California. She is also the Laboratory Director for the Ellison Institute, which is a translational institute that bridges research and innovation by bringing together researchers, patients, and physicians dedicated to improving human health. Although Dr. Mumenthaler’s primary scientific training is in cell biology, she applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians and engineers to explore critical areas in cancer. Her overall research interest focuses on the importance of the tumor microenvironment in influencing tumor progression and treatment response. She is developing physiologically-relevant model systems that capture the microenvironmental context of a tumor and coupling these preclinical models with microscopy-based imaging pipelines to provide deeper insights into the evolving tumor.

Neil Carragher
The University of Edinburgh

Neil Carragher is Professor of Drug Discovery at the University of Edinburgh, he graduated from the University of Aberdeen, Scotland UK in 1992 with a B.Sc Honours degree in the subject of “Cell and Immunobiology”.  He then took up a position within industry at the Yamanouchi Research Institute, Oxford, England UK where he also gained his PhD. He then held consecutive postdoctoral positions within the Department of Pathology, University of Washington, Seattle, USA and at the Beatson Institute for Cancer Research, Glasgow, Scotland UK. In 2004 Neil returned to the pharmaceutical industry as Principal Scientist with the Advanced Science and Technology Laboratory at AstraZeneca where he pioneered early multiparametric high-content phenotypic screening approaches. In 2010 he once again made the career switch from industry to academia and took up the post of Principal Investigator of Drug Discovery at the University of Edinburgh where he leads a research group and is currently co-director of the Edinburgh Cancer Discovery Unit and the Edinburgh Phenotypic Assay Centre. Primary research interests include advancing High-content analysis, phenotypic screening, Reverse Phase Protein Array technology, drug combinations and cancer drug discovery. Neil is also Chief Scientific Officer of the Phenomics Discovery initiative, a public-private consortia to advance phenotypic screening technologies https://npsc.ac.uk/pdi and is a founding member of the European Cell Based Assay Interest group www.eucai.org and global RPPA society.

Bartek Rajwa
Purdue University

Bartek Rajwa has more than 25 years of experience in single-cell analysis, including imaging and flow cytometry. He is a Associate Research Professor of Computational Life Sciences in the Bindley Bioscience Center at Purdue University, where he is conducting studies on the technologies of biological pattern recognition, high-throughput cytometry, high-content imaging, biological-image analysis, and applications of statistical machine learning in cell biology, cancer research, and neuroscience. Dr. Rajwa’s studies employ mathematical models to decipher and interpret complex phenotypic patterns observed via quantitative cell analysis. Working with collaborators, Dr. Rajwa developed new technologies for biological data science, including automated pipelines for clinical flow cytometry analysis, microorganism identification algorithms, and spectral information processing approaches for fluorescence and Raman cytometry. He has also been a co-inventor of two breakthrough hardware technologies: multispectral flow cytometry (licensed by Sony Biotechnology and by Propel Labs.) and elastic light scatter microorganism identification system. Dr. Rajwa is also an Associate Editor of Cytometry Part A (the official journal of the International Society for Advancement of Cytometry), where he is responsible for this journal’s computational cytometry and imaging content.

Todd Shelper
Griffith University

Todd Shelper is a research fellow at the Menzies Health Institute Queensland, working on cell-based therapies for The Spinal Injury Project. He obtained his PhD from Griffith University in 2014 with his project focusing on the development of more physiologically relevant in vitro 3D pancreatic cancer models for use in anti-cancer drug discovery programs. During his time at Griffith University, he has worked on commercial anti-infective high throughput screening and lead optimisation projects. He is actively involved in developing primarily imaging-based assays and has run numerous HTS and HCS campaigns across a range of biology including oncology and parasitology. Todd is currently investigating the therapeutic potential of transplanting olfactory glia in pre-clinical spinal injury models. He has been a board member with the society for 3 years and participated in educational seminars and event planning at the annual SBI2 meetings.

Judi Wardwell
In Sphero

Judi Wardwell-Swanson is a Sr. Application Scientist at InSphero, Inc. where she assists Pharma, Biotech and Academic scientists integrate multicellular 3D models derived from human donor tissues into their drug discovery workflow. In addition to her role as InSphero’s Senior Application Scientist, she also serves as the lead scientist for their high content imaging strategy and technical advisor for their newly acquired imaging platform. Judi has been an active member of SBI2 for 5 years, serving as a Councilor on the Board of Directors from 2016-2019 .

David Gebhard
David Gebhard LLC

Dave has been a practitioner of flow cytometry for forty years and image cytometry for seventeen years. He most recently was in the Primary Pharmacology Group in Pfizer, Groton, CT supporting early drug discovery programs with both flow and image cytometry. He is currently semi-retired and is involved with Cytek Biosciences supporting the Aurora Cytometry platform featuring full spectrum flow cytometry.

Beth Cimini
Broad Institute

Dr. Beth Cimini is the Lead Image Assay Developer for the Imaging Platform at the Broad Institute in Cambridge, MA.  After doing research in visual neuroscience with Dr. William Eldred at Boston University as an undergraduate, she obtained a PhD in Biochemistry and Molecular Biology with Dr. Elizabeth Blackburn at UCSF, studying the difference between splicing variants of the telomere master scaffolding protein TIN2.  These projects honed her interests in image analysis, leading her to join Dr. Anne Carpenter's lab at the Broad, where she leads a team collaborating with approximately 30 outside scientists per year on their own custom image analysis projects.  She also co-maintains the lab's main software tool, CellProfiler, and directs the Broad efforts towards community engagement and driving biological projects for the Center for Open Bioimage Analysis (COBA).

Santosh is currently working as a principal scientist at Pfizer where he is leading compound profiling efforts using cell painting assay. Santosh also has over 9 years of academic and industry experience in high content imaging and analysis field. His experience spans applying HCA in field of protein trafficking, oncology and fibrosis. While working as a scientist at Sanford-Burnham Medical Research Institute (SBMRI), he developed several high content screening assays and was in-charge of assisting biologist with their imaging and analysis protocols. He completed his PhD from University of Toronto in Canada. During his graduate work, he developed several image-analysis pipelines to computationally predict protein localization and quantify associated dynamics. He has also developed image analysis algorithms for fast analysis of 3D organoid images.

Santosh Hariharan
Pfizer
Ty Voss
National Institutes of Health

Ty Voss was a founding member of the National Cancer Institute’s High-Throughput Imaging Facility and served there as head. He then worked as senior applications scientist for the PerkinElmer High-Content Analysis Instrumentation Sales Team. Currently, he assists researchers at the National Center for Advancing Translational Sciences with cell-based assay development and customized automated image analysis.

Chandima Bandaranayaka
Photon Biosciences, LLC

Chandi is currently the Chief Executive Officer at Photon Biosciences, a biotechnology startup. The core technology of Photon Biosciences is a new ultrasensitive detection platform that combines bioengineered proteins with a unique biomineralization process.

Committees 

Educational Material & Webinars

Bartek Rajwa
Dave Gebhard

Meeting program

Chandima Bandaranayaka
Judi Wardwell
Doug Bowman

Membership

Neil Carragher
Steve Haney
Debby Nickisher
Todd Shelper
Chandima Bandaranayaka
Ann Hoffman

Networking, Lounge & Round-table

Neil Carragher
Steve Haney
Debby Nickisher
Bartek Rajwa
Shannon Mumenthaler

Gamification

Debby Nickisher
David Gebhard

Poster session

Shannon Mumenthaler
Neil Carragher
Ty Voss

Marketing and Sponsor Communications

Judi Wardwell
Santosh Hariharan
Chandima Bandaranayaka

Session Speakers and Chairs

Beth Cimini
Paul Johnston
Ann Hoffman
Joe Trask

Exhibit Hall, Marketing, and Conference Theme

Debby Nickisher
Ann Hoffman
Judi Wardwell
Santosh Hariharan
Todd Shelper

Bylaws

Steve Titus
Steve Haney
Jeff Haskins
Myles Fennell
Joe Trask
Ann Hoffman

Standards

Michael Halter
Julie Li
Thierry Dorval
Liz Rubitski
Steve Titus

Jeff Haskins
Todd Shelper
Ty Voss

Publications

Myles Fennell
Paul Johnston
Ann Hoffman